Physician

Ronjay Rakkhit, M.D.

According to 2025 Medicare claims, Ronjay Rakkhit, M.D. (NPI: 1982644498) practices hematology/oncology in the Houston-Pasadena-The Woodlands, TX market, with the plurality of this provider's patient population coming from Harris, TX. This provider's primary affiliated billing organization is ONCOLOGY CONSULTANTS, P. A. (NPI: 1679533418; TIN: 760605200) and primary practice location at 77024-2645. Rakkhit is affiliated with the Baylor Scott & White Quality Alliance (ACO ID: A2542) and Accountable Care Coalition of Southeast Texas, Inc. (ACO ID: D0112), participating under both the MSSP and REACH models.

Rakkhit's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 586 traditional Medicare patients, billed 255,899 HCPCS/CPT codes, and received $3,176,890 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,230 prescription claims across 460 beneficiaries totaling $11,490,110 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 37 claims. Open Payments data shows 68 records totaling $1,555. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,441,788 to $11,490,110. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,864 to $2,565.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	685	270,089	$2,825,809
2016	700	290,522	$2,713,348
2017	714	270,182	$2,982,067
2018	694	332,927	$3,783,252
2019	753	280,346	$3,057,947
2020	601	303,256	$3,456,690
2021	630	245,714	$2,590,726
2022	620	266,612	$2,188,651
2023	576	251,104	$2,690,828
2024	586	255,899	$3,176,890

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	429	2,865	$2,441,788
2016	492	3,148	$2,906,539
2017	493	3,008	$3,637,034
2018	509	3,174	$6,214,946
2019	561	3,765	$9,880,894
2020	520	3,522	$10,547,885
2021	525	3,664	$11,408,941
2022	512	3,687	$10,859,954
2023	461	3,136	$10,959,251
2024	460	3,230	$11,490,110

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	166	$40,025
2016	N/R	134	$23,144
2017	N/R	33	$67,016
2018	N/R	63	$106,922
2019	N/R	37	$4,402
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	107	153	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	455	917	$64
80047	Blood test, basic group of blood chemicals (calcium, ionized)	292	482	$13
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	372	834	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	483	1,462	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	96	2,457	$1,721,547
Xtandi	Enzalutamide	54	1,680	$771,373
Ibrance	Palbociclib	50	1,393	$645,718
Imbruvica	Ibrutinib	33	1,036	$533,951
Brukinsa	Zanubrutinib	38	1,140	$527,255

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	68	$1,555	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ronjay Rakkhit, M.D.?

Tedicare shows public-source Medicare data for Ronjay Rakkhit, M.D. (NPI 1982644498), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ronjay Rakkhit, M.D. have ACO affiliation data?

Ronjay Rakkhit, M.D. is shown with ACO affiliation data for Baylor Scott & White Quality Alliance (MSSP, ACO ID A2542) and Accountable Care Coalition of Southeast Texas, Inc. (REACH, ACO ID D0112).

What billing organization is linked to Ronjay Rakkhit, M.D.?

Ronjay Rakkhit, M.D. is linked to ONCOLOGY CONSULTANTS, P. A. (billing NPI 1679533418) in the available physician profile data.

Does Ronjay Rakkhit, M.D. have Open Payments data?

Ronjay Rakkhit, M.D. has 68 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.